Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
- 10 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 68 (15) , 1197-1204
- https://doi.org/10.1212/01.wnl.0000259034.45049.00
Abstract
Objective: To evaluate the efficacy and safety of retigabine 600, 900, and 1,200 mg/day administered three times daily as adjunctive therapy in patients with partial-onset seizures.Keywords
This publication has 14 references indexed in Scilit:
- Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjectsEuropean Journal of Clinical Pharmacology, 2003
- Multiple‐Dose, Linear, Dose‐Proportional Pharmacokinetics of Retigabine in Healthy VolunteersThe Journal of Clinical Pharmacology, 2002
- Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizuresNeurology, 2001
- D‐23129: A New Anticonvulsant CompoundCNS Drug Reviews, 1996
- D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizuresEuropean Journal of Pharmacology, 1996
- D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizuresEpilepsy Research, 1996
- The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitroEpilepsy Research, 1995
- Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical responseNeuroscience Letters, 1995
- On closed test procedures for dose‐response analysisStatistics in Medicine, 1994
- Statistical Aspects of the Measurement of Clinical Care in EpilepsyPublished by Springer Nature ,1993